BMEA BMEA
Company Profile ↓Company Overview
BMEA (BMEA) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -21.74% |
| 6 Months: | +13.51% |
| 3 Months: | -17.11% |
| 1 Month: | -10.00% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)48.81 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 52.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 1.07B | - | - | - | 1.07B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -398.00K | -295.00K | -1.14M | -3.50M | -5.86M | -8.44M | -12.64M | -14.74M | -16.40M | -17.47M | -23.48M | -26.28M | -30.03M | -27.66M | -31.12M | -37.33M | -41.06M | -38.90M | -34.04M | -30.07M | -29.71M | -21.28M | -20.80M | -12.77M |
| Net Income | -398.00K | -293.00K | -1.14M | -3.50M | -5.85M | -8.40M | -12.61M | -14.71M | -16.37M | -17.26M | -22.89M | -25.31M | -29.05M | -24.89M | -28.43M | -34.88M | -39.06M | -37.28M | -32.79M | -29.30M | -29.26M | -20.74M | -16.41M | -12.41M |
| Diluted EPS | - | - | - | - | -0.49 | -0.33 | -0.43 | -0.51 | -0.56 | -0.59 | -0.78 | -0.86 | -0.98 | -0.70 | -0.80 | -0.98 | -1.09 | -1.03 | -0.91 | -0.81 | -0.80 | -0.51 | -0.27 | -0.17 |
| R&D Expense | 334.00K | 216.00K | 789.00K | 2.33M | 3.80M | 5.22M | 7.89M | 11.09M | 11.35M | 12.58M | 18.24M | 20.54M | 24.39M | 21.94M | 25.35M | 30.87M | 33.78M | 31.82M | 27.24M | 25.24M | 22.90M | 16.57M | 14.40M | 9.12M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | 83.63M | 126.14M | 144.07M | 81.31M |
| Operating Income | -1.20M | -5.33M | - | -83.63M | -126.14M | -144.07M | -81.31M |
| EBITDA | - | - | - | -82.94M | -124.62M | -142.32M | -79.90M |
| Interest Expense | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | -81.83M | -117.25M | -138.43M | -61.80M |
| Tax Provision | - | - | - | - | - | - | - |
| Net Income | -1.20M | -5.32M | - | -81.83M | -117.25M | -138.43M | -61.80M |
| Diluted EPS | - | -0.51 | - | -2.80 | -3.44 | -3.83 | -1.18 |
| R&D Expense | 1.09M | 3.67M | 28.00M | 62.71M | 102.55M | 118.08M | 61.98M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 62.53M | 185.71M | 129.31M | 199.93M | 79.94M | 58.57M |
| Total Equity | -263.00K | -21.00K | 5.17M | 178.78M | 108.54M | 169.24M | 51.57M | 29.55M |
| Cash & Equivalents | - | 239.00K | 61.70M | 145.74M | 111.90M | 176.87M | 58.28M | 55.81M |
| Total Liabilities | - | - | 1.62M | 6.92M | 20.77M | 30.69M | 28.36M | 29.02M |
| Current Liabilities | - | - | 1.62M | 4.64M | 19.10M | 22.86M | 21.67M | 11.10M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.28M | -4.46M | -35.44M | -62.42M | -96.59M | -119.89M | -70.37M |
| Investing Cash Flow | - | -51.00K | -33.35M | 27.34M | -2.22M | -362.00K | - |
| Financing Cash Flow | 1.44M | 65.97M | 153.19M | 1.24M | 163.80M | 1.67M | 67.90M |
| Capital Expenditure | - | -51.00K | -3.17M | -1.03M | -3.37M | -362.00K | - |
| Free Cash Flow | - | -4.51M | -38.61M | -63.45M | -99.96M | -120.26M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | 5,704.8% | -103.0% | - | -75.4% | -69.3% | -268.4% | -209.1% |
| ROCE % | - | -8.7% | - | -75.9% | -71.2% | -247.3% | -171.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BMEA
BMEA Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5tR1NYMkhQbGZVSzdJOVFJY2RUWm1nSjI5QWJFODlVYjFUM3FWSnNqZGlJaTl5MlhRdy0yMkJZejYtcDRmd2xpVUxieVNJTnlDNHdYaGpFQ0xCTlBMZlZhVE9vVWlCSkVRMkoyNGNMSXFkMFVQWkxqVy1R?oc=5" target="_blank">BME…
Analysts Sentiment on Biomea Fusion (BMEA) Remains Strong Amid Strong Diabetes Trial Results - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNb0dXeGtRc1hKdENza2FCQl9hZ3BvdlNLejVPUW50NTVRcnZ1MzF5eWZLWklqWTlVMXpoNVZjaUdmWWxhOTlFS3MzbU5DTEVucVFISFI1QzhRUTF3a2NBVUozV01laXRyc0lERFNkMVJoM1FfNFhWRmJ2akFIVkpwQ2FzSWpMeXE5S3Z3QU…
New diabetes pills show insulin gains and weight-loss potential at ADA - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQSWZvUS1VNjlCZmcwSmtwa2FZVWNfVE81MUhLb1BuQjcwVGUwWC1FYzFkQ19fNWtLbU9UaXBkUmVnV2I2LTZDUklVUnZyZXNmY1c2Tk5pOW5FQmZQQkpVd0piZ1NxV2h0eHZ1VGJZSWxjT19wWVhBVkJlSFNsM0ItYWg4TUNGMnVuS253aF…
Biomea Fusion, Inc. (BMEA) Presents at American Diabetes Association (ADA) 86th Scientific Sessions - Slideshow - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxPbmhmcDJWRlRPajlfejh0SUJBMlEtR2ZjaGxOcVh1VUo5dlFLdWtMNzYxNGlHX2ZvQ3NHUDNwMjNGTE83eU42aHhNanBZUGlLbE95ZndHZGk4c2ZvSVBWYU9raUFSaDljWnF2WTZjLVBRZHAtMUpnMi1zWXBlOEFta3ViU1JaVjd2UURzcW…
Insiders Buying Biomea Fusion Might Wish They Invested More, Stock Gains 12% - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxQS2NfWVp2aDBMaHpsdHlSQ0xiMG5kcnBxeXRxYjRSM2FxRHNObENicGt4dVNhdGFObHBDOVhKOHlUc3VWeE54Z1p2aWRsUDBEV0lHTDRLZmxXV0MzZW9PdGVKYmhBZ3dZTWIzMmZwdVZ1NVZ3VTRocXVFWlZDanljbENTbVh1YmgxZlNNNG…
$BMEA stock is down 10% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPakVtYlVCbllvakVfSlBGdW1mZjNMVkptb1NKazB6VC1kcU5QVUluc1h3RW1vbldVQ3Nza19Fc3c3Rm93Q0QzRGNUVzMybXdub1hwRXJLd19VSzNRQmtTOHc5bzNxd1d1SmRKSnJtSTZzOGJEQTlCUGhWQnBXZVVpaC05aml3eHpsX2NlNk…
BMEA — Frequently Asked Questions
What is the current share price of BMEA?
As of 2026-08-05 17:25 PDT, BMEA trades at $1.26 on NASDAQ/NYSE. Its 52-week range is $0.96 to $2.67.
What is the P/E ratio of BMEA?
BMEA trades at a trailing price-to-earnings (P/E) ratio of -1.07.
Is BMEA a good stock to buy?
This page provides a data-driven analysis of BMEA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.